<DOC>
	<DOC>NCT01604824</DOC>
	<brief_summary>The purpose of this study is to assess the pharmacodynamic (PD) effect of alirocumab on serum low-density lipoprotein cholesterol (LDL-C) in patients with autosomal dominant hypercholesterolemia (ADH) and gain-of-function mutations (GOFm) in 1 or both alleles of the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or with a loss-of-function mutation (LOFm) in 1 or more alleles of the apolipoprotein B-100 gene (apoB).</brief_summary>
	<brief_title>A Study of Alirocumab (REGN727/SAR236553) in Patients With ADH and GOFm of the PCSK9 Gene or LOFm of the apoB Gene</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion criteria include, but are not limited to the following: 1. Between the ages of 18 and 70 years, inclusive 2. A history of molecularly confirmed PCSK9 GOFm for cohort 1 and a history of molecularly confirmed PCSK9 GOFm or ApoB LOFm 3. Plasma LDLCholesterol levels â‰¥70 mg/dL at the screening visit on a lipid lowering therapy (LLT) regimen stable for at least 28 days Exclusion criteria include, but are not limited to the following: 1. Serum triglycerides &gt;350 mg/dL at the screening visit 2. Known to be positive for human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus 3. Pregnant or breastfeeding women. 4. Sexually active man or woman of childbearing potential who is unwilling to practice adequate contraception during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>